canagliflozin

Summary

Summary: A glucoside-derived SODIUM-GLUCOSE TRANSPORTER 2 inhibitor that stimulates urinary excretion of glucose by suppressing renal glucose reabsorption. It is used to manage BLOOD GLUCOSE levels in patients with TYPE 2 DIABETES.

Top Publications

  1. Argento N, Nakamura K. GLYCEMIC EFFECTS OF SGLT-2 INHIBITOR CANAGLIFLOZIN IN TYPE 1 DIABETES PATIENTS USING THE DEXCOM G4 PLATINUM CGM. Endocr Pract. 2016;22:315-22 pubmed publisher
    ..6 years) who were prescribed canagliflozin (CANA) 100 mg daily and had a baseline DCGM 30-day download prior to and a second download after at least 1 ..
  2. Pfeifer M, Townsend R, Davies M, Vijapurkar U, Ren J. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Cardiovasc Diabetol. 2017;16:29 pubmed publisher
    ..The effects of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on pulse pressure, mean arterial pressure, and double ..
  3. Arafa N, Ali E, Hassan M. Canagliflozin prevents scopolamine-induced memory impairment in rats: Comparison with galantamine hydrobromide action. Chem Biol Interact. 2017;277:195-203 pubmed publisher
    b>Canagliflozin (CAN) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated to improve glycemic control in adults with type 2 diabetes mellitus...
  4. Imprialos K, Stavropoulos K, Doumas M, Karagiannis A, Athyros V. The effect of SGLT2 inhibitors on cardiovascular events and renal function. Expert Rev Clin Pharmacol. 2017;10:1251-1261 pubmed publisher
    ..Empagliflozin, and to a lesser extent canagliflozin, resulted in significant reductions of an abundance of cardiovascular mortality and morbidity endpoints...
  5. Hira T, Koga T, Sasaki K, Hara H. Canagliflozin potentiates GLP-1 secretion and lowers the peak of GIP secretion in rats fed a high-fat high-sucrose diet. Biochem Biophys Res Commun. 2017;492:161-165 pubmed publisher
    ..increasing the body weight, respectively, we aimed to analyze the effect of transient inhibition of SGLT1 by canagliflozin on incretin secretion in an obese rat model...
  6. Neal B, Perkovic V, Mahaffey K, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377:644-657 pubmed publisher
    Background Canagliflozin is a sodium-glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes...
  7. Januzzi J, Butler J, Jarolim P, Sattar N, Vijapurkar U, Desai M, et al. Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes. J Am Coll Cardiol. 2017;70:704-712 pubmed publisher
    ..The goal of this study was to examine the effects of canagliflozin on cardiovascular biomarkers in older patients with T2DM...
  8. Ji W, Zhao M, Wang M, Yan W, Liu Y, Ren S, et al. Effects of canagliflozin on weight loss in high-fat diet-induced obese mice. PLoS ONE. 2017;12:e0179960 pubmed publisher
    b>Canagliflozin, an inhibitor of sodium glucose co-transporter (SGLT) 2, has been shown to reduce body weight during the treatment of type 2 diabetes mellitus (T2DM)...
  9. Santos L, Lima F, Sousa Rodrigues C, Barbosa F. Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus. Rev Assoc Med Bras (1992). 2017;63:636-641 pubmed publisher
    ..Although there are several classes of oral antidiabetic agents, most of the patients are outside the therapeutic goal range...

More Information

Publications17

  1. Singh A, Singh R. Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists. Expert Rev Clin Pharmacol. 2017;10:633-647 pubmed publisher
    ..glucose reabsorption by blocking SGLT-2 receptor in kidney, dose-dependently, the highest licensed dose of canagliflozin 300-mg has an additional ability to inhibit SGLT-1 receptor in intestine transiently, that may lead to ..
  2. Novik A V, García B C, Oliva I D. [Diabetic ketoacidosis with mild hyperglycemia associated with the use of canagliflozin. Report of one case with type 1 diabetes]. Rev Med Chil. 2017;145:393-396 pubmed publisher
    ..The patient had used canagliflozin during the two previous months...
  3. De Jonghe S, Johnson M, Mamidi R, Vinken P, Feyen B, Lammens G, et al. Renal tubular and adrenal medullary tumors in the 2-year rat study with canagliflozin confirmed to be secondary to carbohydrate (glucose) malabsorption in the 15-month mechanistic rat study. Chem Biol Interact. 2017;277:85-90 pubmed publisher
    During preclinical development of canagliflozin, an SGLT2 inhibitor, treatment-related pheochromocytomas, renal tubular tumors (RTT), and testicular Leydig cell tumors were reported in the 2-year rat toxicology study...
  4. Majewski C, Bakris G. Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes. Diabetes Care. 2015;38:429-30 pubmed publisher
  5. Kosiborod M, Cavender M, Fu A, Wilding J, Khunti K, Holl R, et al. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotr. Circulation. 2017;136:249-259 pubmed publisher
    ..b>Canagliflozin, dapagliflozin, and empagliflozin accounted for 53%, 42%, and 5% of the total exposure time in the SGLT-2i ..
  6. Bundhun P, Janoo G, Huang F. Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials. BMC Pharmacol Toxicol. 2017;18:19 pubmed publisher
    Nowadays, canagliflozin monotherapy, or in combination with other oral hypoglycemic agents (OHAs), is often administered in patients who are treated for type 2 diabetes mellitus (T2DM)...
  7. Davies M, Merton K, Vijapurkar U, Yee J, Qiu R. Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data. Cardiovasc Diabetol. 2017;16:40 pubmed publisher
    ..The sodium glucose co-transporter 2 inhibitor, canagliflozin, has been shown to improve glycaemic control and reduce body weight and blood pressure (BP) with a favourable ..
  8. Harper W, Clement M, Goldenberg R, Hanna A, Main A, Retnakaran R, et al. Policies, Guidelines and Consensus Statements: Pharmacologic Management of Type 2 Diabetes-2015 Interim Update. Can J Diabetes. 2015;39:250-2 pubmed publisher